<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1118850</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2023.1118850</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Sustained intra-articular reactive oxygen species scavenging and alleviation of osteoarthritis by biocompatible amino-modified tantalum nanoparticles</article-title>
<alt-title alt-title-type="left-running-head">Jiang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe.2023.1118850">10.3389/fbioe.2023.1118850</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Yunsheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1806105/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Junjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1892518/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Xiongbo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Guangxing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dai</surname>
<given-names>Gang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Rong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yao</surname>
<given-names>Chunyan</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1238934/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Jiajia</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Cheng</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gong</surname>
<given-names>Xiaoyuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2130843/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Liu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Center for Joint Surgery</institution>, <institution>Southwest Hospital</institution>, <institution>Third Military Medical University (Army Medical University)</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>State Key Laboratory of Trauma, Burns and Combined Injury</institution>, <institution>Chongqing Engineering Research Center for Nanomedicine</institution>, <institution>Institute of Combined Injury</institution>, <institution>College of Preventive Medicine</institution>, <institution>Third Military Medical University (Army Medical University)</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Key Laboratory of Biorheological Science and Technology</institution>, <institution>Ministry of Education</institution>, <institution>College of Bioengineering</institution>, <institution>Chongqing University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Blood Transfusion Department</institution>, <institution>Southwest Hospital</institution>, <institution>Third Military Medical University (Army Medical University)</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Biomedical Analysis Center</institution>, <institution>Third Military Medical University (Army Medical University)</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>College of Medical Informatics</institution>, <institution>Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/121094/overview">Bin Li</ext-link>, Soochow University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/956651/overview">Jiaxiang Bai</ext-link>, Soochow University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1098219/overview">Sien Lin</ext-link>, The Chinese University of Hong Kong, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xiaoyuan Gong, <email>sliegxy@foxmail.com</email>; Liu Yang, <email>jointsurgery@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>11</volume>
<elocation-id>1118850</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>12</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>01</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Jiang, Li, Yang, Wang, Song, Chen, Dai, Li, Yao, Chen, Chen, Gong and Yang.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Jiang, Li, Yang, Wang, Song, Chen, Dai, Li, Yao, Chen, Chen, Gong and Yang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Recent studies highlight the vital role of oxidative stress and reactive oxygen species (ROS) during progression of osteoarthritis (OA). Attenuating oxidative stress and reducing reactive oxygen species generation in joints represent reasonable strategies for the treatment of osteoarthritis. To address the potential question for clinical translation, and improve the biocompatibility and long-term performance of current antioxidants, the present study provided high biocompatible small positively charged tantalum nanoparticles (Ta-NH<sub>2</sub> NPs) with sustained intra-articular catalase activity and first applied to osteoarthritis intervention. Our <italic>in vitro</italic> results showed that Ta-NH<sub>2</sub> NPs were stable with good biocompatibility, and protected viability and hyaline-like phenotype in H<sub>2</sub>O<sub>2</sub>-challenged chondrocytes. In addition, the <italic>in vivo</italic> biodistribution data demonstrated a sustained retention of Ta-NH<sub>2</sub> NPs in the joint cavity, particularly in articular cartilage without organ toxicity and abnormality in hemogram or blood biochemistry indexes. Finally, compared with catalase (CAT), Ta-NH<sub>2</sub> NPs exhibited long-term therapeutic effect in monosodium iodoacetate (MIA) induced osteoarthritis model. This study preliminarily explored the potential of simply modified metal nanoparticles as effective reactive oxygen species scavenging agent for osteoarthritis intervention, and offered a novel strategy to achieve sustained reactive oxygen species suppression using biocompatible Ta-based nano-medicine in oxidative stress related diseases.</p>
</abstract>
<kwd-group>
<kwd>tantalum nanoparticles</kwd>
<kwd>catalase activity</kwd>
<kwd>ROS scavenging agent</kwd>
<kwd>oxidative stress</kwd>
<kwd>osteoarthritis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Osteoarthritis (OA) is the most common form of joint diseases with manifestations of chronic joint inflammation (<xref ref-type="bibr" rid="B33">Tamaddon et al., 2020</xref>), and may result in pain, joint malformation and limited mobility in patients (<xref ref-type="bibr" rid="B28">Quicke et al., 2022</xref>). OA is the leading cause of long-term disability in adults, and the prevalence of OA is estimated to reach 40%. OA is characterized by morphological, biochemical, molecular and biomechanical changes of both cells and extracellular matrix (ECM) in articular cartilage, synovium, and subchondral bone (<xref ref-type="bibr" rid="B33">Tamaddon et al., 2020</xref>). Although the mechanisms of OA initiation and progression are yet to be understood, recent studies have highlighted the vital role of oxidative stress and reactive oxygen species (ROS) in mitochondrial dysfunction (<xref ref-type="bibr" rid="B40">Yao et al., 2021</xref>), chondrocyte senescence, matrix synthesis (<xref ref-type="bibr" rid="B29">Rahmati et al., 2017</xref>), synovial inflammation (<xref ref-type="bibr" rid="B31">Sanchez-Lopez et al., 2022</xref>), and subchondral bone dysfunction during progression of OA. Oxidative stress has been defined as a disturbance in the balance between the production of ROS and antioxidant defences, which results in macromolecular damage and disruption of redox signalling (<xref ref-type="bibr" rid="B38">Yang et al., 2020</xref>). Oxidative stress amplifies inflammatory responses and exacerbates cartilage breakdown (<xref ref-type="bibr" rid="B39">Yang et al., 2022</xref>). Attenuating the oxidative stress level by antioxidants drugs or natural antioxidants could effectively decrease the progression of OA in animal models (<xref ref-type="bibr" rid="B13">Gui et al., 2022</xref>). Therefore, attenuating oxidative stress and reducing ROS generation in joints represent promising strategies for the treatment of OA.</p>
<p>Currently, antioxidant supplementations (<xref ref-type="bibr" rid="B13">Gui et al., 2022</xref>), mediators of various ROS pathways (<xref ref-type="bibr" rid="B38">Yang et al., 2020</xref>), and free radical scavengers have been successively utilized to target oxidative stress in the pathogenesis of OA (<xref ref-type="bibr" rid="B14">Guill&#xe9;n et al., 2021</xref>). Among them, the commonly used antioxidants are simply divided into macro and small molecules. However, systemic application of these antioxidants might related to poor safety, pharmacodynamics, and bioavailability (<xref ref-type="bibr" rid="B4">Brown et al., 2019</xref>). ROS scavenging therapy for OA is thus administered by intra-articular injection. However, in addition to instability of these antioxidant caused by fluctuation in osteoarthritic physicochemical microenvironment, small molecules are rapidly cleared from the joint within hours <italic>via</italic> the synovial vasculature, and large molecules are cleared through the synovial lymphatic vessels within days (<xref ref-type="bibr" rid="B12">Gerwin et al., 2006</xref>). Therefore, high-dosage injections are often required to achieve the desired working concentration (<xref ref-type="bibr" rid="B11">Gammer and Brob&#xe4;ck, 1984</xref>). To overcome these shortcomings and prolong the action of antioxidant for further clinical application, inorganic metal nano-enzyme such as ultrafine copper oxide (<xref ref-type="bibr" rid="B22">Liu T. et al., 2020</xref>) and Fe-curcumin nanozyme (<xref ref-type="bibr" rid="B41">Yuan et al., 2022</xref>) were developed and have displayed good bioavailability and excellent therapeutic efficiency at very low concentration (&#x2248;nM/mL). However, the potential disadvantages such as ionization in body fluid (<xref ref-type="bibr" rid="B24">Matusiewicz, 2014</xref>) and long-term metal cumulation of toxic side effects (<xref ref-type="bibr" rid="B30">Ring et al., 2016</xref>; <xref ref-type="bibr" rid="B3">Badhe et al., 2021</xref>) still impede its clinical application.</p>
<p>Tantalum (Ta) is an inert metal with strong corrosion resistance and excellent biocompatibility (<xref ref-type="bibr" rid="B18">Levine et al., 2006</xref>; <xref ref-type="bibr" rid="B9">Dou et al., 2019</xref>). Ta-based implantations are widely used in joint replacement and bone defect repair. Unlike cobalt and titanium, Ta-based implants have been reported to maintain an excellent long-term biocompatibility (<xref ref-type="bibr" rid="B18">Levine et al., 2006</xref>). In addition to the application in tissue engineering, tantalum nanoparticles (Ta-NPs) have also gained reasonable attention in early diagnosis and photothermal therapy of malignant tumour due to its high biocompatibility. For instance, recent studies have demonstrated that tantalum oxide NPs are an excellent contrast agent for computed tomography (CT) (<xref ref-type="bibr" rid="B27">Oh et al., 2011</xref>). In addition, 2D Ta carbide (<xref ref-type="bibr" rid="B6">Dai et al., 2017</xref>) and Ta carbide nanosheets (<xref ref-type="bibr" rid="B21">Liu et al., 2018</xref>) have been explored as light-induced therapeutic agents for tumour diagnosis and therapy. Interestingly, studies also suggest that Ta-coated surfaces could effectively alleviate oxidative stress induced by a high-glucose environment in a diabetes model (<xref ref-type="bibr" rid="B35">Wang et al., 2016</xref>), what&#x2019;s interesting is that the some research reported the similar properties to catalase of Ta-NPs (<xref ref-type="bibr" rid="B26">Miao et al., 2019</xref>). The aforementioned properties endow Ta-NPs with the ability to effectively alleviate oxidative stress by eliminating H<sub>2</sub>O<sub>2</sub>-induced ROS, and make it possible for its application in the treatment of OA.</p>
<p>Based on the mentioned advantages of Ta, the present study designed Ta-NPs with amino-modification for OA-related oxidative stress modulation. To highlight the potential for clinical translation, the surface of Ta-NPs was modified by amino group (Ta-NH<sub>2</sub> NPs) with silane-coupling approach. The positive charged Ta-NPs were designed to retain in negatively charged cartilaginous ECM (<xref ref-type="bibr" rid="B4">Brown et al., 2019</xref>), enabling the continuous and steady regulation of the oxidative stress level in osteoarthritic joint. We hypothesize that the Ta-NH<sub>2</sub> NPs alleviate OA progression in monosodium iodoacetate (MIA)-induced OA rat model (<xref ref-type="fig" rid="F1">Figure 1</xref>). The <italic>in vitro</italic> antioxidative effect of Ta-NPs was evaluated by hydrogen peroxide decomposition analysis and ROS staining. The regulation of Ta-NH<sub>2</sub> NPs on chondrocyte phenotype was verified by western blotting and immunostaining experiments. In addition, near-infrared fluorescence <italic>in vivo</italic> imaging, complete blood panel analysis and serum biochemistry test, micro-CT and histological analysis were employed to verify the efficiency, safety and therapeutic effect of Ta-NPs after intra-articular injection.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Schematic diagram of the synthesis of Ta-NH<sub>2</sub> NPs and the treatment of OA with single intra-articular injection. Positively charged NPs obtained by adding amino groups to the surface of Ta was injected into the osteoarthritic joint cavity. Ta-NH<sub>2</sub> NPs exhibit long-term oxidative stress attenuating effect in articular cartilage, and alleviates OA progression.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g001.tif"/>
</fig>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Materials</title>
<p>Ta NPs, collagenase II and hydrogen peroxide solution were purchased from Sigma (United States). Catalase, Alcian blue staining solution, Crystal violet staining solution, Hydrogen peroxide detection kit, Reactive oxygen species assay kit, Phosphate-buffered saline (PBS), Penicillin-streptomycin solution (P/S), 4% paraformaldehyde fix solution, immunostaining permeabilization buffer with Triton X-100, QuickBlock primary/secondary antibody dilution buffer for immunofluorescence/Western blot, immunol staining/Western blot wash buffer, QuickBlock blocking buffer, soaking and activation buffer for polyvinylidene fluoride (PVDF) membrane, SDS-PAGE gel preparation kit, BCA protein assay kit, and DAPI staining solution were obtained from Beyotime (China). Absolute ethyl alcohol was gained from MACKLIN (China). DMEM/High glucose medium, fetal bovine serum (FBS), trypsin, and dimethyl sulfoxide (DMSO) were purchased from Gibco (United States). (3-Aminopropyl) trimethoxysilane was purchased from Aladdin (China). Cell counting kit-8 was purchased from Dojindo Laboratories (Japan). Calcein-AM/PI double stain kit was purchased from Bestbio (China). The primary antibody against collagen I (COL-I), collagen II (COL-II), aggrecan (ACAN), SOX-9, iNOS, ADAMTS-5, MMP-13, &#x3b2;-action were purchased from Affinity (China). Goat Anti-Rabbit IgG H&#x26;L (Alexa Fluor<sup>&#xae;</sup>488) was purchased from Abcam (United States). Ethylene Diamine Tetraacetic Acid (EDTA) was purchased from Biosharp (China). CY5.5 staining were purchased from Ruixi (China). All chemicals were of reagent grade.</p>
</sec>
<sec id="s2-2">
<title>Surface amino modification of Ta NPs</title>
<p>The surface of Ta NPs was modified with amino group using the silane-coupling method. Briefly, Ta NPs (1&#xa0;g) were dispersed in ethanol (10&#xa0;mL) under tip ultrasound for 20&#xa0;min, followed by centrifugation (800&#xa0;g, 5&#xa0;min) to remove large sized NPs. The concentration of collected solution was determined with oven drying method and diluted to 1&#xa0;mg/mL with ethanol. (3-Aminopropyl) trimethoxysilane (100&#xa0;&#x3bc;L) was added into Ta NPs (20&#xa0;mL) and stirred for another 3&#xa0;h at 70&#xb0;C. Finally, Ta-NH<sub>2</sub> NPs were obtained by centrifugation (12,000&#xa0;g, 5&#xa0;min) and washed with deionized water to remove the free (3-Aminopropyl) trimethoxysilane for three times.</p>
</sec>
<sec id="s2-3">
<title>Characterization of Ta and Ta-NH<sub>2</sub> NPs</title>
<p>The morphology of Ta NPs and Ta-NH<sub>2</sub> NPs was observed using Hitachi S-3400NIISEM (Hitachi, Japan) at 2&#xa0;kV accelerating voltage. Transmission electron microscope (TEM) and element mapping images were conducted by JEM 2100F (JEOL, Japan). The hydrodynamic sizes, particle dispersity index (PDI), and zeta-potential of Ta-NH<sub>2</sub> NPs were analyzed with the Malvern Zetasizer Nano ZS instrument (Malvern, United Kingdom). Fourier transforms infrared (FT-IR) spectra of Ta-NH<sub>2</sub> NPs were measured using Nicolet IS 10 spectrometer (Nicolet, United States). X-ray diffraction (XRD) of Ta-NH<sub>2</sub> NPs was detected by an X-ray diffractometer D8 ADVANCE (Bucker, Germany) with the 2-Thera range from 10&#xb0; to 90&#xb0;. X-ray photoelectron spectroscopy (XPS) of Ta-NH<sub>2</sub> NPs was determined by an X-ray photoelectron spectrometer 250Xi (Thermo Fisher, United States).</p>
</sec>
<sec id="s2-4">
<title>H<sub>2</sub>O<sub>2</sub> scavenging activity assay</title>
<p>H<sub>2</sub>O<sub>2</sub> scavenging activity of Ta-NH<sub>2</sub> NPs was tested by the Hydrogen Peroxide Detection Kit. Ta-NH<sub>2</sub> NPs with different concentrations (0, 10, 20, 50, and 100&#xa0;&#x3bc;g/mL) were incubated with 1&#xa0;mM H<sub>2</sub>O<sub>2</sub> at 37&#xb0;C for 1&#xa0;h, respectively. After reaction, the concentration of remained H<sub>2</sub>O<sub>2</sub> was determined according to the manufacturer&#x2019;s instructions, and the scavenging capacity was calculated. For assessment of Ta-NH<sub>2</sub> NPs with stable H<sub>2</sub>O<sub>2</sub> scavenging activity, Ta-NH<sub>2</sub> NPs (100&#xa0;&#x3bc;g/mL) were incubated with 1&#xa0;mM H<sub>2</sub>O<sub>2</sub> under different temperature (25&#xb0;C, 37&#xb0;C, 50&#xb0;C, and 60&#xb0;C) and pH (2, 4, 6, 7, 8, and 10), respectively.</p>
</sec>
<sec id="s2-5">
<title>Isolation of chondrocyte and cell culture</title>
<p>All animal experiments were performed in accordance with the guidelines approved by the Laboratory Animal Welfare and Ethics Committee of Army Medical University (Chongqing, China). The methods of chondrocytes isolation were in accordance with the previously published article. Male Sprague-Dawley (SD) rats (200&#x2013;300&#xa0;g) were suffocated by CO<sub>2</sub>, and knee joint was dissected. The cartilage was broken up with ophthalmic scissors and digested by type II collagenase for 12&#xa0;h. After filtering out cartilage residue, primary chondrocytes were obtained. The obtained chondrocytes were cultured with Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100&#xa0;&#x3bc;g/mL streptomycin, and 100&#xa0;U/mL penicillin at 37&#xb0;C in 5% CO<sub>2</sub> incubator. The experimental cells were selected as P2 generation rat chondrocytes.</p>
</sec>
<sec id="s2-6">
<title>
<italic>In vitro</italic> cytotoxicity evaluation of Ta-NH<sub>2</sub> NPs</title>
<p>The cytotoxicity of Ta-NH<sub>2</sub> NPs was determined by the CCK-8 assay <italic>in vitro</italic>. Briefly, chondrocytes (1 &#xd7; 10<sup>4</sup> per well) were seeded into 96-well culture plates and incubated at 37&#xb0;C in an 5% CO<sub>2</sub> incubator for 24&#xa0;h. Different concentrations of Ta-NH<sub>2</sub> NPs (0, 5, 10, 20, 50, 100, 200, and 500&#xa0;&#x3bc;g/mL) were added to each well and incubated for another 24&#xa0;h or 48&#xa0;h. The cell viability was then quantified by measuring the absorbance value at 450&#xa0;nm with microplate reader.</p>
</sec>
<sec id="s2-7">
<title>Detection of intracellular ROS</title>
<p>Chondrocytes (1 &#xd7; 10<sup>5</sup> per dish) were seeded into confocal petri dish and pre-treated with Ta-NH<sub>2</sub> NPs (100&#xa0;&#x3bc;g/mL) for 2&#xa0;h. 400&#xa0;&#x3bc;M H<sub>2</sub>O<sub>2</sub> was then added into petri dish and cells were incubated for another 24&#xa0;h. After washing with PBS, cells were stained with DCFH-DA probes following the manufacturer&#x2019;s instructions and subjected to flow-cytometry detection.</p>
</sec>
<sec id="s2-8">
<title>Immunofluorescence staining</title>
<p>The above-described cells were washed with PBS, and fixed with 4% paraformaldehyde, followed by blockage with Quick Blocking buffer. Next, the cells were incubated with primary antibody (COL-I, COL-X, COL-II, SOX-9, ACAN, MMP-13, ADAMTS-5, and RUNX-2) and then with secondary antibody. Nuclei were stained with DAPI. The fluorescence images were observed with laser scanning confocal microscope, and the relative fluorescence intensity was analyzed with ImageJ (version 1.52p). The immunofluorescence staining work concentration of COL-I, COL-II, ACAN, SOX-9, iNOS, ADAMTS-5 and MMP-13 was 1:100. The immunofluorescence staining work concentration of Goat Anti-Rabbit IgG H&#x26;L (Alexa Fluor<sup>&#xae;</sup>488) was 1:200.</p>
</sec>
<sec id="s2-9">
<title>Western blot analysis</title>
<p>The total proteins were isolated from above-described cells using RIPA lysis, and were quantified using BCA protein kit according to the manufacturer&#x2019;s instructions. The protein was separated by SDS PAGE and subsequently transferred to PVDF membrane. Next, the cell lysis was incubated with primary antibody (COL-I, COL-X, COL-II, SOX-9, ACAN, MMP-13, ADAMTS-5, and RUNX-2), followed by secondary antibody incubation. Finally, the membranes were visualized using ultrasensitive ECL and the intensity of blots was quantified with Image Lab software (version 3.0). The WB work concentration of COL-I, COL-II, ACAN, SOX-9, iNOS, ADAMTS-5 and MMP-13 was 1:1000, and &#x3b2;-action was 1:10,000. Goat Anti-Rabbit IgG H&#x26;L (HRP) WB work concentration was 1:5000.</p>
</sec>
<sec id="s2-10">
<title>Fluorescence <italic>in vivo</italic> imaging</title>
<p>To determine the retention time of Ta-NH<sub>2</sub> NPs in the articular joint, female SD rats&#x2019; (250&#x2013;300&#xa0;g) knees were injected with 100&#xa0;&#x3bc;L of Ta-NH<sub>2</sub> NPs-CY5.5 (100&#xa0;&#x3bc;g/mL). The fluorescence images were captured at various time points (1, 3, 7, 14, and 28 d) using <italic>In Vivo</italic> Imaging System Pearl Trilogy (LI-COR, United States). The knee joint, femur condyles, and major organs (heart, liver, spleen, lung, kidney, and brain) were harvested for <italic>ex vivo</italic> NIR imaging. The relative fluorescence intensities were analyzed using Image Studio (version 5.2).</p>
</sec>
<sec id="s2-11">
<title>
<italic>In vivo</italic> toxicity evaluation of Ta-NH<sub>2</sub> NPs</title>
<p>Blood samples were harvested at day 1 and 28 after intra-articular injection of 100&#xa0;&#x3bc;L of Ta-NH<sub>2</sub> NPs. The serum biochemistry tests included two important indicators of hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and two indicators of kidney function: blood urea nitrogen (BUN) and creatinine (CRE). Complete blood count was done to further evaluate the <italic>in vivo</italic> toxicity of Ta-NH<sub>2</sub> NPs. Furthermore, the harvested major organs (liver, heart, spleen, lung, kidney, and brain) were subjected to hematoxylin and eosin (H&#x26;E) staining and histological analysis.</p>
</sec>
<sec id="s2-12">
<title>MIA-induced OA model and Ta-NH<sub>2</sub> NPs intraarticular injection</title>
<p>The rat OA model was induced by intra-articular injection 20&#xa0;&#x03BC;L of MIA (2&#xa0;mg/mL). The next experiment will be conducted 2&#xa0;weeks after injection. Rats were randomly divided into 4 groups (<italic>n</italic> &#x3d; 8): Control group (Intra-articular injection of PBS), MIA group (Intra-articular injection of MIA), MIA &#x2b; Ta-NH<sub>2</sub> NPs group (Intra-articular injection of MIA, followed by Ta-NH<sub>2</sub> NPs treatment), and MIA &#x2b; CAT group (Intra-articular injection of MIA, followed by CAT treatment). Rats were sacrificed after treatment with Ta-NH<sub>2</sub> NPs or CAT for 4 or 8&#xa0;weeks. The knee joints were collected and fixed in 4% paraformaldehyde.</p>
</sec>
<sec id="s2-13">
<title>Micro CT imaging</title>
<p>The knee joints were scanned with micro-CT (viva CT-40, ScancoMedical AG, Switzerland). Image acquisition was performed with the condition of 45&#xa0;kV and 177&#xa0;&#x3bc;A in high-resolution scans (10.5&#xa0;&#x3bc;m voxel resolution). Two-dimensional images were used to generate three-dimensional reconstructions. The epiphysis of the tibial subchondral bone was manually chosen as the region of interest during three-dimensional analysis (micro-CT Evolution Program V6.5 software). The three-dimensional parameters of trabecular bone, including bone volume fraction (BV/TV, %), trabecular thickness (Tb.Th, mm). Interest area (10&#xa0;mm, 10&#xa0;mm, 5&#xa0;mm) was selected with software, and this area was limited to the upper surface of the specimens.</p>
</sec>
<sec id="s2-14">
<title>Histological analysis</title>
<p>The knee joints were decalcified in 10 wt% ethylene diamine tetraacetic acid (EDTA) solution for 4&#xa0;weeks at 25&#xb0;C. To observe the degeneration of knee articular cartilage, synovial inflammation and corresponding inducible nitric oxide synthases (iNOS) changes, H&#x26;E, Safranin-o-fast green staining, and immune-histochemical staining against iNOS were performed respectively. Three independent experts were asked to perform double-blind scoring according to OA Research Society International (OARSI) scoring system.</p>
</sec>
<sec id="s2-15">
<title>Statistical analysis</title>
<p>Graphical results were displayed as mean &#xb1; s.d by using GraphPad prism software (version 7.0). All data were assessed for normality using the Kolmogorov-Smirnov test and for homoscedasticity using the F-test. The statistical significance difference between two groups was compared by independent-sample <italic>t</italic>-test for parametric data, and by Mann-Whitney test for non-parametric data. The Welch&#x2019;s correction was applied for variables with unequal variance. The statistical significance differences bet ween vehicle and other treatment groups were determined by One-way ANOVA test and Fisher&#x2019;s LSD post-test for parametric data, and by Kruskal Wallis test and Dunn&#x2019;s multiple comparisons post-test for non-parametric data. In all cases, statistical significance was defined with <italic>p</italic> &#x3c; 0.05.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and discussion</title>
<sec id="s3-1">
<title>Ta-NH<sub>2</sub> NPs synthesis and characterization</title>
<p>Pristine Ta NPs with high density have poor colloidal stability in common aqueous (<xref ref-type="bibr" rid="B26">Miao et al., 2019</xref>). To improve the colloidal stability of Ta NPs and increase their retention in negatively charged articular cartilage ECM (<xref ref-type="bibr" rid="B10">Freedman et al., 2014</xref>), the surface of Ta NPs was modified with amino group. Ta-NH<sub>2</sub> NPs were synthesized by a simple and efficient silane-coupling approach, which is widely used for modification of the surface of inorganic NPs (<xref ref-type="bibr" rid="B36">Wu et al., 2020</xref>). In detail, the commercial raw Ta NPs were dispersed in ethanol and then centrifugated to separate large-sized NPs. Amino groups were coated on the surface of Ta NPs by refluxing reaction with (3-Aminopropyl) trimethoxysilane in ethanol. From scanning electron microscopy (SEM) (<xref ref-type="fig" rid="F2">Figures 2A</xref>, <xref ref-type="fig" rid="F2">B</xref>) images, Ta-NH<sub>2</sub> NPs exhibited uniform monodispersed compared with Ta NPs. Meanwhile, in consistent with previous report (<xref ref-type="bibr" rid="B26">Miao et al., 2019</xref>), as shown in the TEM image (<xref ref-type="sec" rid="s11">Supplementary Figure S1A</xref>), the Ta NPs and Ta-NH<sub>2</sub> NPs were observed with irregular elliptical morphology. HR-TEM elemental mapping images (<xref ref-type="sec" rid="s11">Supplementary Figure S1B</xref>) indicated that Ta, O, and N elements were uniformly distributed in Ta-NH<sub>2</sub> NPs. Whereas only elemental Ta and O emerged in Ta NPs, verifying the successful modification of amino group on Ta NPs surface. As shown in <xref ref-type="fig" rid="F2">Figure 2C</xref>, the hydrodynamic sizes of Ta NPs and Ta-NH<sub>2</sub> NPs determined by dynamic light scattering (DLS) were 116.73 &#xb1; 0.31 and 168.77 &#xb1; 8.04&#xa0;nm with a narrow PDI (0.18 &#xb1; 0.01 vs. 0.16 &#xb1; 0.01), respectively. Meanwhile, the zeta potential changed from negative (Ta NPs, &#x2212;36.63 &#xb1; 1.31&#xa0;mV) to positive charge (Ta-NH<sub>2</sub> NPs, 32.27 &#xb1; .51&#xa0;mV) (<xref ref-type="fig" rid="F2">Figure 2D</xref>), which could be explained by the modification of Ta NPs with amino group ligands spreading out in solutions. As shown in the XRD patterns (<xref ref-type="fig" rid="F2">Figure 2E</xref>), Ta-NH<sub>2</sub> NPs maintained all the characteristic peaks of the Ta NPs at high angles of 30&#xb0;-80&#xb0;, indicated that the modification of amino group on Ta NPs surface did not decrease the crystalline purity of Ta NPs. In addition, from FT-IR spectra (<xref ref-type="fig" rid="F2">Figure 2F</xref>), the Ta-NH<sub>2</sub> NPs appeared new characteristic bands around 3,300&#xa0;cm<sup>&#x2212;1</sup> of -NH<sub>2</sub>, confirming that amino group had been successfully bonded on the surface of Ta NPs. In addition, the chemical valence of Ta<sub>2</sub>O<sub>5</sub> and metallic Ta were detected at 28&#xa0;eV (Ta<sub>4</sub>f<sub>7/2</sub>) and 26&#xa0;eV (Ta<sub>4</sub>f<sub>5/2</sub>) from the XPS spectra (<xref ref-type="fig" rid="F2">Figure 2G</xref>), which could be attributed to partial oxidation on the surface of Ta NPs and turned into a more stable form (<xref ref-type="bibr" rid="B34">Tsuchiya et al., 2011</xref>). The oxygenic groups on metal surface were beneficial to the reaction of silane with surface oxygenic groups of Ta NPs. Meanwhile, the chemical valence of N elements also could be observed at 470&#xa0;eV (N1s) from the XPS spectra, further confirming the successful modification of NH<sub>2</sub> on Ta NPs surface. As shown in <xref ref-type="fig" rid="F2">Figure 2H</xref>, Ta-NH<sub>2</sub> NPs exhibited stable dispersion in H<sub>2</sub>O for 5&#xa0;days. Furthermore, no obvious hydrodynamic particle size change was observed in Ta-NH<sub>2</sub> NPs after incubation in H<sub>2</sub>O for 5&#xa0;days, indicating a good colloidal stability (<xref ref-type="fig" rid="F2">Figure 2I</xref>). Taken together, our data demonstrated that amino groups had been successfully decorated on the surface of Ta NPs with improved colloidal stability.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Morphological and compositional characterizations of Ta-NH<sub>2</sub> NPs. <bold>(A)</bold> SEM image of Ta NPs and <bold>(B)</bold> SEM image of Ta-NH<sub>2</sub> NPs. <bold>(C)</bold> Hydrodynamic diameters and <bold>(D)</bold> Zeta potential of Ta NPs and Ta-NH<sub>2</sub> NPs measured by DLS. <bold>(E)</bold> XRD patterns and <bold>(F)</bold> FT-IR spectra of Ta NPs and Ta-NH<sub>2</sub> NPs. <bold>(G)</bold> XPS spectra of Ta-NH<sub>2</sub> NPs, <bold>(H)</bold> Representative digital photographs of Ta NPs and Ta-NH<sub>2</sub> NPs at 0 d and 5 d. <bold>(I)</bold> Hydrodynamic diameters of Ta-NH<sub>2</sub> NPs measured by DLS at 1&#x2013;5 d.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>H<sub>2</sub>O<sub>2</sub> scavenging activity of Ta-NH<sub>2</sub> NPs</title>
<p>H<sub>2</sub>O<sub>2</sub>, the representative ROS was selected to investigate the ROS scavenging activity of Ta-NH<sub>2</sub> NPs <italic>in vitro</italic>. As shown in <xref ref-type="fig" rid="F3">Figure 3A</xref>, 1&#xa0;mM H<sub>2</sub>O<sub>2</sub> was reacted with different concentration of Ta-NH<sub>2</sub> NPs at 37&#xb0;C for 1&#xa0;h. Ta-NH<sub>2</sub> NPs exhibited ROS scavenging activity in a concentration-dependent manner. Approximately 35% of the H<sub>2</sub>O<sub>2</sub> was decomposed by 50&#xa0;&#x3bc;g/mL Ta-NH<sub>2</sub> NPs, and almost 40% H<sub>2</sub>O<sub>2</sub> could be scavenged in the concentration 100&#xa0;&#x3bc;g/mL with excellent pH and temperature stabilities (<xref ref-type="fig" rid="F3">Figures 3B</xref>, C). When Ta-NH<sub>2</sub> NPs were co-cultured with H<sub>2</sub>O<sub>2</sub>, a large number of bubbles were generated in the tube during H<sub>2</sub>O<sub>2</sub> decomposition due to the surface effect of Ta-NPs, or similar to the internal electronic transition of cerium oxide, while the specific mechanism is worthy of further exploration and study (<xref ref-type="sec" rid="s11">Supplementary Figure S2A</xref>). Compared with the working concentrations of reported metal NPs, recently reported ultrasmall copper oxide (<xref ref-type="bibr" rid="B22">Liu T. et al., 2020</xref>) and manganese dioxide NPs (<xref ref-type="bibr" rid="B15">Kumar et al., 2019</xref>) might manifest better catalytic efficiency than Ta-NH<sub>2</sub> NPs. However, these reported metal nanomaterials might be ionized by body fluid to generate free metal ions, which further led to element imbalance or even metal poisoning (<xref ref-type="bibr" rid="B30">Ring et al., 2016</xref>; <xref ref-type="bibr" rid="B3">Badhe et al., 2021</xref>). In addition, compared with classical metal such as gold NPs (<xref ref-type="bibr" rid="B19">Li et al., 2017</xref>), Ta-NH<sub>2</sub> NPs showed stronger H<sub>2</sub>O<sub>2</sub> decomposition. In the present study, compared with traditional antioxidants, the stability analysis indicated that the H<sub>2</sub>O<sub>2</sub> scavenging of Ta-NH<sub>2</sub> NPs was not influenced by pH or temperature. It is well known that the activities of ROS scavenging in traditional biological enzymes were affected by the microenvironment of joint cavity, and this drawback might affect the therapeutic outcome due to the fluctuation in physical and chemical properties of osteoarthritic joints.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>H<sub>2</sub>O<sub>2</sub> scavenging activity and <italic>in vitro</italic> biocompatibility of Ta-NH<sub>2</sub> NPs. <bold>(A)</bold> Concentration dependent H<sub>2</sub>O<sub>2</sub> scavenging activity of Ta-NH<sub>2</sub> NPs during 1&#xa0;h incubation. <bold>(B)</bold> pH and <bold>(C)</bold> temperature stabilities of H<sub>2</sub>O<sub>2</sub> scavenging activity in Ta-NH<sub>2</sub> NPs (100&#xa0;&#x3bc;g/mL). <bold>(D)</bold> Chondrocyte viability under different Ta-NH<sub>2</sub> NPs concentration treatments. <bold>(E,F)</bold> Western blot analysis of hyaline (COL-II, SOX-9, and ACAN), <bold>(G,H)</bold> hypertrophic and catabolic (MMP-13, RUNX-2, and ADAMTS-5) phenotypes of chondroyte after 24&#xa0;h of Ta-NH<sub>2</sub> NPs treatment. <bold>(I)</bold> Morphology, Live/Dead Krystal violet, Alcian blue, and COL-II/ACAN immunofluorescence staining of chondrocytes treated with Ta-NH<sub>2</sub> NPs. Data were represented as means &#xb1; s.d, from three independent replicates. &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>The biocompatibility of Ta-NH<sub>2</sub> NPs <italic>in vitro</italic>
</title>
<p>The biocompatibility of Ta-based materials has been widely validated in orthopedic implants. In the present study, our <italic>in vitro</italic> biocompatibility analysis suggested that Ta-NH<sub>2</sub> NPs also shared the same characteristics in bio-safety. The CCK-8 assay results showed no significant cytotoxicity at test concentration after 24 and 48&#xa0;h co-culture (<xref ref-type="fig" rid="F3">Figure 3D</xref>). But slightly decreased chondrocyte viability was noticed when concentration reached 200&#xa0;&#x3bc;g/mL. Chondrocytes cultured with Ta-NH<sub>2</sub> NPs did not manifest obvious morphology change (<xref ref-type="fig" rid="F3">Figure 3I</xref>). Crystal violet staining, alcian blue staining, and immunofluorescent staining of COL-II and ACAN results indicated that Ta-NPs treatment did not affect the deposition of cartilaginous ECM (<xref ref-type="fig" rid="F3">Figure 3I</xref>). However, western blot (<xref ref-type="fig" rid="F3">Figures 3E</xref>, G) results showed that there were significant decreases in protein levels of COL-II, SOX-9, RUNX-2, and ADAMTS-5. Subsequent quantitative analysis further supported these results (<xref ref-type="fig" rid="F3">Figures 3F</xref>, H). This observation suggests that small amount of ROS has a positive significance for the physiological regulation of cells under normal physiological conditions (<xref ref-type="bibr" rid="B32">Sies and Jones, 2020</xref>), Ta-NH<sub>2</sub> NPs may break the ROS balance after co-culture with normal chondrocytes. As for the specific reasons, it remains to be further explored.</p>
</sec>
<sec id="s3-4">
<title>Ta-NH<sub>2</sub> NPs protects viability and hyaline-like phenotype in chondrocyte under oxidative stress <italic>in vitro</italic>
</title>
<p>During the progression of OA, iNOS from OA-affected cartilage may contribute to the inflammation and pathogenesis of cartilage destruction (<xref ref-type="bibr" rid="B38">Yang et al., 2020</xref>). Chondrocytes showed over expression of iNOS mainly in the superficial zone in unhealthy OA cartilage (<xref ref-type="bibr" rid="B1">Amin et al., 1995</xref>). Expression of iNOS could reflect the degree of oxidative stress (<xref ref-type="bibr" rid="B38">Yang et al., 2020</xref>). To investigate the inhibitory effect of Ta-NH<sub>2</sub> NPs on iNOS and ROS production in chondrocytes under oxidative stress, we pre-treated cells with Ta-NH<sub>2</sub> NPs (100&#xa0;&#x3bc;g/mL) or catalase (CAT, 100&#xa0;&#x3bc;g/mL) for 1&#xa0;h. Cells were then challenged with H<sub>2</sub>O<sub>2</sub> for 24&#xa0;h (400&#xa0;&#x3bc;M). DCFH-DA staining indicated significant increase in intra-cellular ROS level in H<sub>2</sub>O<sub>2</sub> treated group (<xref ref-type="fig" rid="F4">Figure 4A</xref>), which was inhibited by either Ta-NH<sub>2</sub> NPs or CAT. In agreement with previous studies, our data showed significant increase in iNOS expression post H<sub>2</sub>O<sub>2</sub> challenge. While pre-treatment with Ta-NH<sub>2</sub> NPs, but not CAT reversed the iNOS level (<xref ref-type="fig" rid="F4">Figure 4B</xref>). In addition, live and dead staining data (<xref ref-type="sec" rid="s11">Supplementary Figure S2B</xref>) indicated Ta-NH<sub>2</sub> NPs or CAT pre-treatment successfully protected chondrocytes viability <italic>via</italic> inhibiting intra-cellular ROS production. These data suggested that although Ta-NH<sub>2</sub> NPs and CAT showed similar protective effect under oxidative stress, different mechanism might be involved.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Ta-NH<sub>2</sub> NPs and CAT reduced oxidative stress and maintained the chondrogenic phenotype of H<sub>2</sub>O<sub>2</sub>-stimulated chondrocytes. Fluorescence staining of <bold>(A)</bold> ROS, iNOS, ACAN and COL-II, <bold>(B)</bold> COL-I, ADAMTS-5, RUNX-2 and MMP-13 in H<sub>2</sub>O<sub>2</sub> stimulated chondrocytes with or without Ta-NH<sub>2</sub> NPs and CAT pretreatments. <bold>(C,D)</bold> Quantitative analyses of fluorescence intensity. <bold>(E)</bold> Western blot assay of protein expressions in above-described chondrocytes. <bold>(F,G)</bold> Quantitative analyses of protein expressions. Data were represented as means &#xb1; s.d, from three independent replicates. &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g004.tif"/>
</fig>
<p>In the aspect of phenotypic alternation, our immunofluorescence staining and Western blot results (<xref ref-type="fig" rid="F4">Figures 4A</xref>, <xref ref-type="fig" rid="F4">B</xref>, E) suggested that H<sub>2</sub>O<sub>2</sub> significantly decreased the hyaline-like phenotype in chondrocytes, while increased fibrotic (COL-I) and catabolism (ADAMTS-5, RUNX-2, and MMP-13) markers (<xref ref-type="bibr" rid="B5">Charlier et al., 2019</xref>; <xref ref-type="bibr" rid="B20">Lian et al., 2019</xref>). Further quantitative analysis suggested the similar results (<xref ref-type="fig" rid="F4">Figures 4C</xref>, D, F, G). It is worth mentioning that fibrosis and hypertrophy are important pathological change in osteoarthritic cartilage (<xref ref-type="bibr" rid="B38">Yang et al., 2020</xref>; <xref ref-type="bibr" rid="B39">Yang et al., 2022</xref>). Previous studies have revealed that reduction of oxidative stress attenuated fibrosis and hypertrophy indexes effectively in tissue-organ level, including liver (<xref ref-type="bibr" rid="B37">Xu et al., 2022</xref>), kidney (<xref ref-type="bibr" rid="B23">Liu Z. et al., 2020</xref>), and heart (<xref ref-type="bibr" rid="B8">Dey et al., 2018</xref>). Similar to CAT, Ta-NH<sub>2</sub> NPs inhibited the increment in protein levels of COL-I, RUNX-2, and MMP-13 (<xref ref-type="fig" rid="F4">Figure 4E</xref>), and maintained the hyaline-like phenotype (ACAN and COL-II) in H<sub>2</sub>O<sub>2</sub>-treated chondrocytes. Compared with CAT group, it is worth noticing that Ta-NH<sub>2</sub> NPs group showed more significant increase in COL-II, and decrease in ADAMTS-5 and MMP-13 protein levels. The observation indicated that Ta-NH<sub>2</sub> NPs were more capable of restoring the balance between catabolism and anabolism. This effect of Ta-NH<sub>2</sub> NPs might be attributed to the inhibitory ability of Ta-NH<sub>2</sub> NPs in iNOS expression. Previous study suggested that NO promoted degradation of ECM by enhancing the activity of matrix metalloproteinase (MMPs) that subsequently led to joint destruction (<xref ref-type="bibr" rid="B17">Lepetsos and Papavassiliou, 2016</xref>). H<sub>2</sub>O<sub>2</sub> leads to chondrocyte apoptosis by disrupting mitochondria, reducing mtDNA integrity and repair capacity. Small-sized Ta NPs could enter cell plasma, and possibly into mitochondria (<xref ref-type="sec" rid="s11">Supplementary Figure S3A</xref>), reducing the negative effect of hydrogen peroxide on mitochondria through redox properties. In arthritic tissues, the NF-&#x3ba;B signaling pathway can be activated by pro-inflammatory cytokines, mechanical stress, and ECM degradation products. The NF-&#x3ba;B signaling pathway affects cartilage matrix remodeling (<xref ref-type="bibr" rid="B2">Arra et al., 2020</xref>), chondrocyte apoptosis, synovial inflammation, and has an indirect stimulating effect on downstream regulators of terminal chondrocyte differentiation. The interaction between redox signaling and NF-&#x3ba;B transcription factors appears to play a unique role in the pathogenesis of OA (<xref ref-type="bibr" rid="B38">Yang et al., 2020</xref>). Activation of NF-&#x3ba;B inhibits chondrocyte anabolism and triggers the expression of multiple matrix-degrading proteases, such as metalloproteases and ADAMTS, leading to erosion of articular cartilage (<xref ref-type="bibr" rid="B7">Deng et al., 2018</xref>). In addition, the expression of iNOS is also strongly related to NF-&#x3ba;B, which enhances the production of synovial iNOS, produces a large amount of NO, and mediates the expression of OA synovial inflammatory factors. Combined with our results, in addition to relying on its redox in mitochondria, Ta NPs might maintain the cell state by affecting the NF-&#x3ba;B pathway.</p>
</sec>
<sec id="s3-5">
<title>
<italic>In vivo</italic> biodistribution and biocompatibility assessment of Ta-NH<sub>2</sub> NPs</title>
<p>Currently, drug delivery by intra-articular injection suffers from short retention in the joint cavity (<xref ref-type="bibr" rid="B4">Brown et al., 2019</xref>). Small molecules are rapidly cleared from the joint cavity within hours <italic>via</italic> synovial vasculature, and macromolecules within days <italic>via</italic> synovial lymphatics (<xref ref-type="bibr" rid="B12">Gerwin et al., 2006</xref>). In order to achieve stable pharmacokinetics, increased dosage or repetitive injection are often necessary (<xref ref-type="bibr" rid="B11">Gammer and Brob&#xe4;ck, 1984</xref>). In addition to biocompatibility, the ideal therapeutic antioxidant should also have high efficiency and long-term effect. In the present study, the positively charged NPs were designed to prolong the retention of Ta-NPs in articular cartilage. As shown in <xref ref-type="fig" rid="F5">Figure 5A</xref>, after intra-articular injection of Cy5.5 labelled Ta-NH<sub>2</sub> NPs (100&#xa0;&#x3bc;g/mL) and CAT (100&#xa0;&#x3bc;L), <italic>in vivo</italic> fluorescence imaging indicated that gradually decreased concentration of both antioxidants at day 1, 3, 7, 14, and 28. Whereas the Cy5.5 dye alone showed rapid decrease in fluorescence intensity 1&#xa0;h post injection (<xref ref-type="sec" rid="s11">Supplementary Figure S4A</xref>). Compared with CAT group (at day 3), significantly longer joint retention (at day 28) of Ta-NH<sub>2</sub> NPs was noticed. In addition, further analysis in dissected knee joints confirmed that Cy5.5 labelled Ta-NH<sub>2</sub> NPs, but not Cy5.5 labelled CAT (<xref ref-type="sec" rid="s11">Supplementary Figure S4B</xref>) was still detectable 28 d post injection in femoral articular cartilage (<xref ref-type="fig" rid="F5">Figures 5B</xref>, C). Agreed with previous study, these data confirmed the positively charged Ta NPs were able to stay in the joint cavity, particularly in the articular cartilage. From the imaging of the dissected femoral condyle, sustained fluorescence over 28 d observational period outlined the shape of trochlear cartilage, indicating that Ta-NPs after amino modification could be adsorbed in the surface of the articular cartilage.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Metabolic kinetics of Ta-NH<sub>2</sub> NPs in knee joints and biodistribution in main organs of SD rats. <italic>In vivo</italic> fluorescence imaging of cy5.5-labelled Ta-NH<sub>2</sub> NPs and CAT in <bold>(A)</bold> intact, cy5.5-labelled Ta-NH<sub>2</sub> NPs in <bold>(B)</bold> dissected rat knee joints, and <bold>(C)</bold> femoral condyles from 1 to 28&#xa0;days post single intra-articular injection. Fluorescence quantifications of intact <bold>(D)</bold> and dissected <bold>(E)</bold> knee joints and femoral condyles <bold>(F)</bold> post intra-articular injection. <bold>(G)</bold> Biodistribution of Ta-NH<sub>2</sub> NPs and corresponding <bold>(H)</bold> fluorescence quantification in major organs during 1&#x2013;28&#xa0;days post single intra-articular injection. Data were represented as means &#xb1; s.d., from three independent replicates.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g005.tif"/>
</fig>
<p>To further explore the biocompatibility and potential organ toxicity of Ta-NH<sub>2</sub> NPs, we analyzed the biodistribution in main organs. Liver, heart, spleen, lung, kidney, and brain from rat post intra-articular injection of Cy5.5 labelled Ta-NH<sub>2</sub> NPs were tested. No hemorrhage, atrophy, or necrosis was found in the analyzed organs. At the macroscopic level, Ta-NH<sub>2</sub> NPs were mainly accumulated in the liver, spleen and kidney. Among them, the fluorescence intensity in spleen, liver and kidney reached the peak at day 1, 3, and 7 post injection and decayed by day 3, 7, and 14 respectively. This observation suggested that Ta-NH<sub>2</sub> NPs in the organ might be gradually metabolized. To evaluate the organ toxicity of Ta-NH<sub>2</sub> NPs, histological analysis was employed. H&#x26;E staining of main organs indicated no necrosis, congestion, or hemorrhage in the heart, liver, spleen, and lung at day 1, 3, 7, 14, and 28 (<xref ref-type="sec" rid="s11">Supplementary Figure S4</xref>) after single dose intra-articular injection of Ta NPs (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Moreover, no distinguishable inflammatory, lesion or tissue damage was observed in the glomerulus, tubules, collecting ducts, and urethra, illustrating the excellent biocompatibility of Ta-NH<sub>2</sub> NPs. To further explore functional changes of these organs, the hemogram (<xref ref-type="fig" rid="F6">Figures 6D&#x2013;G</xref>&#x2013;<xref ref-type="fig" rid="F6">G</xref>) and blood biochemistry analysis was performed. We selected AST and ALT, CRE and BUN to reflect the liver and renal functions, respectively. Compared with control group, our data showed no significant alternation in the size, number, and composition of blood cells, and in AST, ALT (<xref ref-type="fig" rid="F6">Figure 6B</xref>), BUN, and CRE levels (<xref ref-type="fig" rid="F6">Figure 6C</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>
<italic>In vivo</italic> biocompatibility assessment of Ta-NH<sub>2</sub> NPs. <bold>(A)</bold>. Evaluation of <italic>in vivo</italic> toxicity of Ta-NH<sub>2</sub> NPs to major organs (heart, liver, spleen, and lung) at 1 d after knee joint injection. Serum levels of liver function indicators: aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) 1 d and 28 d after injection <bold>(B)</bold>. Serum levels of kidney function indicators: blood urea nitrogen (BUN) and creatinine (CRE) 1 d and 28 d after injection <bold>(C)</bold>. <bold>(D&#x2013;G)</bold> Blood parameters in normal rat and rat knee joint injected with Ta-NH<sub>2</sub> NPs 1 d and 28 d after injection. In <bold>(B&#x2013;E)</bold>, data were represented as means &#xb1; s.d., from three independent replicates.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g006.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>
<italic>In vivo</italic> therapeutic effect of Ta-NH<sub>2</sub> NPs in MIA induced OA model</title>
<p>As shown in <xref ref-type="sec" rid="s11">Supplementary Figure S6</xref>, the rat OA model was induced by MIA injection, followed by the corresponding antioxidant injection. At 8&#xa0;weeks post injection, compared with that in the sham operation group, the micro-CT scanning indicated obvious bone defects in the patella and femoral condyle, and alternation in subchondral bone structure in vehicle group (<xref ref-type="fig" rid="F7">Figure 7A</xref>, white arrows). The subchondral bone structure was significantly improved by Ta-NH<sub>2</sub> NPs or CAT injection (<italic>p</italic> &#x3c; 0.05, <xref ref-type="fig" rid="F7">Figures 7B</xref>, C).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Ta-NH<sub>2</sub> NPs restored MIA-induced bone structure and alleviated the inflammation in synovium in rat model. <bold>(A)</bold> Micro-CT images of the MIA pretreated knee joints after single articular injection of Ta-NH<sub>2</sub> NPs or CAT. <bold>(B,C)</bold> Statistic analysis of Bone value/Tissue value and Trabecular thickness. <bold>(D,E)</bold> iNOS immunohistochemical and H&#x26;E staining of articular cartilage, subchondral bone, synovium and H&#x26;E staining of synovial tissue at 4 and 8 weeks post treatments. <bold>(F,G)</bold> Histopathological scoring of synovium at 4 and 8&#xa0;weeks post treatments. The arrow points to the synovium and hyperplasia blood vessels. Data were represented as means &#xb1; s.d., from three or five independent replicates (One-way ANOVA). &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g007.tif"/>
</fig>
<p>In order to verify the long-term anti-oxidative stress effect of Ta-NH<sub>2</sub> NPs post single intra-articular injection, iNOS expression was detected in articular cartilage, subchondral bone and synovium during the entire process (<xref ref-type="fig" rid="F7">Figures 7D</xref>, E). The expression of iNOS in articular cartilage was significantly increased, and the expression reached the peak at the 8th&#xa0;week after MIA injection (<xref ref-type="fig" rid="F7">Figure 7E</xref>). Antioxidant treatment decreased the expression of iNOS, particularly in Ta-NH<sub>2</sub> NPs treated group. In addition, Ta-NH<sub>2</sub> NPs, but not CAT showed prolonged inhibition of iNOS expression at the 8th week after MIA injection (<xref ref-type="fig" rid="F7">Figure 7E</xref>). Cartilage is the main source of NO in OA (<xref ref-type="bibr" rid="B25">Melchiorri et al., 1998</xref>), and iNOS expression is more enhanced in chondrocytes compared with synovial cells from patients with OA (<xref ref-type="bibr" rid="B25">Melchiorri et al., 1998</xref>). In addition, expression of iNOS is mainly concentrated in the superficial osteoarthritic cartilage region (<xref ref-type="bibr" rid="B1">Amin et al., 1995</xref>), whereas chondrocytes isolated from patients without OA do not express iNOS. Our data were in line with these observations, in which we showed iNOS expression was mainly confined to articular cartilage, especially in the superficial zone. The cartilage-targeting ability of Ta-NH<sub>2</sub> NPs can penetrate through cartilage (<xref ref-type="sec" rid="s11">Supplementary Figures S3B, C</xref>) and might act through direct oxidation resistance in the ECM, or reduce intracellular iNOS synthesis <italic>via</italic> phagocytosis. The iNOS expression in synovium tissue was similar to cartilage, whereas no significant difference in iNOS expression in subchondral bone was noticed (<xref ref-type="fig" rid="F7">Figures 7D</xref>, E).</p>
<p>The synovium is a thin connective tissue that attaches to the joints, its inflammation is mediated by activation of mitochondrial dysfunction (<xref ref-type="bibr" rid="B31">Sanchez-Lopez et al., 2022</xref>), cytokines, and metabolites in synovial cells. The inter-communication between chondrocytes and synovial cells is thought to be significant to joint homeostasis (<xref ref-type="bibr" rid="B16">Kurowska-Stolarska and Alivernini, 2022</xref>). Once synovitis is activated, cartilage undergoes subsequent adverse changes. In addition to the immunohistochemical staining of iNOS, we further observed synovial inflammation and angiogenesis by H&#x26;E staining (<xref ref-type="fig" rid="F7">Figures 7D</xref>, E). It was not difficult to notice the MIA-induced synovial inflammation. In vehicle group, obvious hyperplasia and inflammatory cell infiltration were seen in synovium at 4&#xa0;weeks post intra-articular injection. In addition, vessel hyperplasia was also noticed at 8&#xa0;weeks. The inflammation of the synovium was alleviated after both anti-oxidative treatments. Notably, synovitis score indicated synovial inflammation in the Ta-NH<sub>2</sub> NPs group was significantly lower than that in the CAT group at 8&#xa0;weeks post injection (<xref ref-type="fig" rid="F7">Figures 7F</xref>, G).</p>
<p>The further evaluation of the therapeutic effect of Ta-NH<sub>2</sub> NPs in MIA-induced OA model was based on H&#x26;E and safranin-o-fast green staining. As shown in <xref ref-type="fig" rid="F8">Figures 8A</xref>, <xref ref-type="fig" rid="F8">B</xref>, the vehicle group presented typical OA features such as surface irregularity, decreased expression of glycosaminoglycans, and cartilage defects. These cartilage damages were alleviated after antioxidant treatment. The Ta-NH<sub>2</sub> NPs treatment presented sustained remission at week 8, while CAT treatment did not exert its antioxidant function at this time point, which was consistent with previous results. Compared with vehicle group, both antioxidants attenuated the OARSI score in femur, and significantly decreased the OARSI score in tibia (<xref ref-type="fig" rid="F8">Figures 8C</xref>, D). In addition, Ta-NH<sub>2</sub> NPs exhibited excellent long-term therapeutic effect as evidenced by more homogeneous glycosaminoglyc and cell arrangement (<italic>p</italic> &#x3c; .05 when compared with CAT group).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Therapeutic efficiency of Ta-NH<sub>2</sub> NPs on MIA-induced OA. <bold>(A)</bold> H&#x26;E staining and <bold>(B)</bold> Safranin-O-Fast Green Staining of articular joints from each group. The box marked local magnification. OARSI score of <bold>(C)</bold> femur and <bold>(D)</bold> tibia at 4 and 8&#xa0;weeks post treatments. Data were represented as means &#xb1; s.d., from five independent replicates (One-way ANOVA), &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fbioe-11-1118850-g008.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>To overcome the disadvantages of current antioxidative strategy for OA, the present study designed and prepared positively charged Ta NPs with sustained intra-articular catalase activity. The <italic>in vitro</italic> results showed that our designed Ta-NH<sub>2</sub> NPs had good biocompatibility and stability, and protected viability and hyaline-like phenotype in chondrocyte under oxidative stress. Our hypothesis was agreed with <italic>in vivo</italic> biodistribution data that Ta-NH<sub>2</sub> NPs showed sustained retention in the joint cavity, particularly in articular cartilage. Finally, Ta-NH<sub>2</sub> NPs exhibited long-term anti-oxidant stress and therapeutic effects in MIA-induced OA model. This study proposes a promising cartilage-protective approach to reduce oxidative stress in OA cartilage. Ta-NH<sub>2</sub> NPs were designed to retain in cartilaginous ECM without inducing cytotoxicity or adverse reactions <italic>in vitro</italic> and <italic>in vivo</italic>. Given their joint retention time and ROS clearance capacity, these NPs might be used to treat or prevent OA. Our study provides a promising strategy for antioxidant therapy in OA, which is expected to be translated into clinical application in the future.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Ethics statement</title>
<p>The animal study was reviewed and approved by Laboratory Animal and Welfare Ethics Committee of the Third Military Medical University.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>YJ, TL, XS, and JY conceived and designed the study. Experiments supervised by XG and LY. Experimental performed by YJ, TL, JC, and XW. YJ, TL, and GC analysed the data. Manuscript was revised by XG, LY, GD, RL, CC, and CY.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This research was funded by Chongqing Talent Project (CQYC20210101319), Nature Science Foundation of Chongqing (cstc2021jcyj-msxmX0135).</p>
</sec>
<ack>
<p>We thank the technical support in histologic staining offered by Knorigene Technologies.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fbioe.2023.1118850/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fbioe.2023.1118850/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Cesare</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vyas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Attur</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tzeng</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Billiar</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>1995</year>). <article-title>The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase</article-title>. <source>J. Exp. Med.</source> <volume>182</volume> (<issue>6</issue>), <fpage>2097</fpage>&#x2013;<lpage>2102</lpage>. <pub-id pub-id-type="doi">10.1084/jem.182.6.2097</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Swarnkar</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Otero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>3427</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-17242-0</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badhe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Akinfosile</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bijukumar</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Barba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mathew</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Systemic toxicity eliciting metal ion levels from metallic implants and orthopedic devices - a mini review</article-title>. <source>Toxicol. Lett.</source> <volume>350</volume>, <fpage>213</fpage>&#x2013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2021.07.004</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Intra-articular targeting of nanomaterials for the treatment of osteoarthritis</article-title>. <source>Acta Biomater.</source> <volume>93</volume>, <fpage>239</fpage>&#x2013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2019.03.010</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charlier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Deroyer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ciregia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Malaise</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Neuville</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Plener</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chondrocyte dedifferentiation and osteoarthritis (OA)</article-title>. <source>Biochem. Pharmacol.</source> <volume>165</volume>, <fpage>49</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2019.02.036</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Two-dimensional tantalum carbide (MXenes) composite nanosheets for multiple imaging-guided photothermal tumor ablation</article-title>. <source>ACS Nano</source> <volume>11</volume> (<issue>12</issue>), <fpage>12696</fpage>&#x2013;<lpage>12712</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.7b07241</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Reciprocal inhibition of YAP/TAZ and NF-&#x3ba;B regulates osteoarthritic cartilage degradation</article-title>. <source>Nat. Commun.</source> <volume>9</volume> (<issue>1</issue>), <fpage>4564</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-07022-2</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>DeMazumder</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sidor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>O&#x27;Rourke</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure</article-title>. <source>Circ. Res.</source> <volume>123</volume> (<issue>3</issue>), <fpage>356</fpage>&#x2013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1161/circresaha.118.312708</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Effect of porous tantalum on promoting the osteogenic differentiation of bone marrow mesenchymal stem cells <italic>in&#xa0;vitro</italic> through the MAPK/ERK signal pathway</article-title>. <source>J. Orthop. Transl.</source> <volume>19</volume>, <fpage>81</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.jot.2019.03.006</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lusic</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grinstaff</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Tantalum oxide nanoparticles for the imaging of articular cartilage using X-ray computed tomography: visualization of <italic>ex vivo</italic>/<italic>in vivo</italic> murine tibia and <italic>ex vivo</italic> human index finger cartilage</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>53</volume> (<issue>32</issue>), <fpage>8406</fpage>&#x2013;<lpage>8410</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201404519</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gammer</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Brob&#xe4;ck</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1984</year>). <article-title>Clinical comparison of orgotein and methylpredisolone acetate in the treatment of osteoarthrosis of the knee joint</article-title>. <source>Scand. J. Rheumatol.</source> <volume>13</volume> (<issue>2</issue>), <fpage>108</fpage>&#x2013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.3109/03009748409100372</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerwin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hops</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lucke</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Intraarticular drug delivery in osteoarthritis</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>58</volume> (<issue>2</issue>), <fpage>226</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2006.01.018</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chhay</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Superoxide dismutase-loaded porous polymersomes as highly efficient antioxidant nanoparticles targeting synovium for osteoarthritis therapy</article-title>. <source>Biomaterials</source> <volume>283</volume>, <fpage>121437</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121437</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guill&#xe9;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tofi&#xf1;o-Vian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Silvestre</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castej&#xf3;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alcaraz</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Role of peroxiredoxin 6 in the chondroprotective effects of microvesicles from human adipose tissue-derived mesenchymal stem cells</article-title>. <source>J. Orthop. Transl.</source> <volume>30</volume>, <fpage>61</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.jot.2021.08.003</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Adjei</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liseth</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Manganese dioxide nanoparticles protect cartilage from inflammation-induced oxidative stress</article-title>. <source>Biomaterials</source> <volume>224</volume>, <fpage>119467</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119467</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurowska-Stolarska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alivernini</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>18</volume> (<issue>7</issue>), <fpage>384</fpage>&#x2013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-022-00790-8</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lepetsos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Papavassiliou</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>ROS/oxidative stress signaling in osteoarthritis</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1862</volume> (<issue>4</issue>), <fpage>576</fpage>&#x2013;<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.01.003</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sporer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poggie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Della Valle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Experimental and clinical performance of porous tantalum in orthopedic surgery</article-title>. <source>Biomaterials</source> <volume>27</volume> (<issue>27</issue>), <fpage>4671</fpage>&#x2013;<lpage>4681</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2006.04.041</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kawazoe</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>TEMPO-conjugated gold nanoparticles for reactive oxygen species scavenging and regulation of stem cell differentiation</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>9</volume> (<issue>41</issue>), <fpage>35683</fpage>&#x2013;<lpage>35692</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.7b12486</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Collagen type II suppresses articular chondrocyte hypertrophy and osteoarthritis progression by promoting integrin &#x3b2;1-SMAD1 interaction</article-title>. <source>Bone Res.</source> <volume>7</volume>, <fpage>8</fpage>. <pub-id pub-id-type="doi">10.1038/s41413-019-0046-y</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>2D superparamagnetic tantalum carbide composite MXenes for efficient breast-cancer theranostics</article-title>. <source>Theranostics</source> <volume>8</volume> (<issue>6</issue>), <fpage>1648</fpage>&#x2013;<lpage>1664</lpage>. <pub-id pub-id-type="doi">10.7150/thno.23369</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>2788</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-16544-7</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>An ultrasmall RuO2 nanozyme exhibiting multienzyme-like activity for the prevention of acute kidney injury</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>12</volume> (<issue>28</issue>), <fpage>31205</fpage>&#x2013;<lpage>31216</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c07886</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matusiewicz</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Potential release of <italic>in vivo</italic> trace metals from metallic medical implants in the human body: from ions to nanoparticles--a systematic analytical review</article-title>. <source>Acta Biomater.</source> <volume>10</volume> (<issue>6</issue>), <fpage>2379</fpage>&#x2013;<lpage>2403</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2014.02.027</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melchiorri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meliconi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Frizziero</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Silvestri</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pulsatelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mazzetti</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>1998</year>). <article-title>Enhanced and coordinated <italic>in vivo</italic> expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis</article-title>. <source>Arthritis Rheum.</source> <volume>41</volume> (<issue>12</issue>), <fpage>2165</fpage>&#x2013;<lpage>2174</lpage>. <pub-id pub-id-type="doi">10.1002/1529-0131(199812)41:12&#x3c;2165::aid-art11&#x3e;3.0.co;2-o</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>PEGylated tantalum nanoparticles: A metallic photoacoustic contrast agent for multiwavelength imaging of tumors</article-title>. <source>Small</source> <volume>15</volume> (<issue>41</issue>), <fpage>e1903596</fpage>. <pub-id pub-id-type="doi">10.1002/smll.201903596</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Piao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided sentinel lymph node mapping</article-title>. <source>J. Am. Chem. Soc.</source> <volume>133</volume> (<issue>14</issue>), <fpage>5508</fpage>&#x2013;<lpage>5515</lpage>. <pub-id pub-id-type="doi">10.1021/ja200120k</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quicke</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Conaghan</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Corp</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peat</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Osteoarthritis year in review 2021: epidemiology &#x26; therapy</article-title>. <source>Osteoarthr. Cartil.</source> <volume>30</volume> (<issue>2</issue>), <fpage>196</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2021.10.003</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahmati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nalesso</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mobasheri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mozafari</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Aging and osteoarthritis: Central role of the extracellular matrix</article-title>. <source>Ageing Res. Rev.</source> <volume>40</volume>, <fpage>20</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2017.07.004</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ring</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>O&#x27;Mullane</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>O&#x27;Riordan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Furey</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Trace metal determination as it relates to metallosis of orthopaedic implants: Evolution and current status</article-title>. <source>Clin. Biochem.</source> <volume>49</volume>, <fpage>617</fpage>&#x2013;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2016.01.001</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Lopez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Coras</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Guma</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Synovial inflammation in osteoarthritis progression</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>18</volume> (<issue>5</issue>), <fpage>258</fpage>&#x2013;<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-022-00749-9</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sies</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Reactive oxygen species (ROS) as pleiotropic physiological signalling agents</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>21</volume> (<issue>7</issue>), <fpage>363</fpage>&#x2013;<lpage>383</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-0230-3</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamaddon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gilja</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Osteochondral scaffolds for early treatment of cartilage defects in osteoarthritic joints: from bench to clinic</article-title>. <source>Biomater. Transl.</source> <volume>1</volume> (<issue>1</issue>), <fpage>3</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.3877/cma.j.issn.2096-112X.2020.01.002</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuchiya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Glans</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>X-ray absorption, photoemission spectroscopy, and Raman scattering analysis of amorphous tantalum oxide with a large extent of oxygen nonstoichiometry</article-title>. <source>Phys. Chem. Chem. Phys.</source> <volume>13</volume> (<issue>38</issue>), <fpage>17013</fpage>&#x2013;<lpage>17018</lpage>. <pub-id pub-id-type="doi">10.1039/c1cp21310e</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Promotion of osteointegration under diabetic conditions by tantalum coating-based surface modification on 3-dimensional printed porous titanium implants</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>148</volume>, <fpage>440</fpage>&#x2013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2016.09.018</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Chitosan-miRNA functionalized microporous titanium oxide surfaces via a layer-by-layer approach with a sustained release profile for enhanced osteogenic activity</article-title>. <source>J. Nanobiotechnol.</source> <volume>18</volume> (<issue>1</issue>), <fpage>127</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-020-00674-7</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Multiplexing nanodrug ameliorates liver fibrosis via ROS elimination and inflammation suppression</article-title>. <source>Small</source> <volume>18</volume> (<issue>3</issue>), <fpage>e2102848</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202102848</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Natural ingredients-derived antioxidants attenuate H2O2-induced oxidative stress and have chondroprotective effects on human osteoarthritic chondrocytes via Keap1/Nrf2 pathway</article-title>. <source>Free Radic. Biol. Med.</source> <volume>152</volume>, <fpage>854</fpage>&#x2013;<lpage>864</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.01.185</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Tropoelastin improves adhesion and migration of intra-articular injected infrapatellar fat pad MSCs and reduces osteoarthritis progression</article-title>. <source>Bioact. Mater.</source> <volume>10</volume>, <fpage>443</fpage>&#x2013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2021.09.011</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Chondrocyte ferroptosis contribute to the progression of osteoarthritis</article-title>. <source>J. Orthop. Transl.</source> <volume>27</volume>, <fpage>33</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.jot.2020.09.006</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Fe-curcumin nanozyme-mediated reactive oxygen species scavenging and anti-inflammation for acute lung injury</article-title>. <source>ACS Cent. Sci.</source> <volume>8</volume> (<issue>1</issue>), <fpage>10</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.1c00866</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>